Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-919 in healthy Japanese adults for COVID-19 prevention
jRCT2071200069Phase 2Completed
- Sponsor
- Takeda
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing TAK-919 with Placebo (2 arms). Primary endpoints: Percentage of participants with solicited local adverse events following first vaccination, Percentage of participants with solicited local adverse events following second vaccination and 12 more. Started Jan 2021; status: completed.
02
Drugs
DNL919
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071200069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200069.